About
Ryan Watts is the co-founder and CEO of Denali Therapeutics, a neuroscience-focused biotech company building medicines for neurodegenerative and rare neurologic diseases. In interviews, he describes Denali's focus on Alzheimer's, Parkinson's, ALS, Hunter syndrome, and blood-brain-barrier delivery technologies, and says he previously worked at Genentech in oncology and neurodegeneration.
Areas of interest
biotechneuroscienceneurodegenerationAlzheimer's diseaseParkinson's diseaseALSlysosomal storage disordersdrug deliveryblood-brain barrierhuman geneticsaging